Virgin Media (VMED), Liberty Global (LBTYA) Boards Approve Deal - Faber
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Virgin Media (VMED) Acquired by Liberty Global (LBTYA) in $23.3B Deal
February 5, 2013 9:30 PM ESTIn a deal highly anticipated throughout the day, Virgin Media, Inc. (NASDAQ: VMED) announced an agreement Tuesday evening to be acquired by Liberty Global, Inc. (NASDAQ: LBTYA) for $23.3 billion in cash and stock.
The combined company will create one of the leading broadband communications company, covering 47 million homes and serving 25 million customers across 14 countries. The deal will be accretive to free cash flow.
The company... More
Billionaire John Malone & Co. in Talks to Acquire UK Cable Business (LBTYA) (VMED)
February 5, 2013 9:53 AM ESTIn what may shape up to be the largest media deal so far this year, reports late on Tuesday said Virgin Media (NASDAQ: VMED), a cable company in the UK, and Liberty Global (NASDAQ: LBTYA) (NASDAQ: LBTYB) were in talks about a potential merger. This morning Virgin... More
StreetInsider.com Pre-Open Movers 02/05: (OPXA) (PLX) (VMED) Higher; (HEB) (YUM) (JCP) Lower (more...)
February 5, 2013 9:41 AM ESTOpexa Therapeutics, Inc. (NASDAQ: OPXA) 300% HIGHER; announced the execution of an agreement with Merck Serono, a division of Merck, Darmstadt, Germany, for the development and commercialization of Tcelna (imilecleucel-T), a potential first-in-class personalized T-cell therapy for patients suffering from multiple sclerosis (MS). Tcelna (imilecleucel-T) is being developed by Opexa and currently is in a Phase IIb clinical trial in patients with Secondary Progressive MS (SPMS). Potential payments to Opexa from the option and license agreement could total $225 million based upon the successful development and commercialization of Tcelna for MS.
... More
Virgin Media (VMED) Confirms in Talks with Liberty Global (LBTYA)
February 5, 2013 7:00 AM ESTVirgin Media Inc. (NASDAQ: VMED) notes the recent press speculation in relation to a possible corporate transaction between Virgin Media Inc. and Liberty Global, Inc. (NASDAQ: LBTYA).
Virgin Media confirms that it is in discussions with Liberty Global,... More
